Pfizer Inc. and Valneva SE today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is...
Read More